You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Special Topics in HER2-Positive Breast Cancer

  • Authors: Reshma L. Mahtani, DO; Alexandra Zimmer, MD; Michael F. Press, MD, PhD; Chau T. Dang, MD; Ian Krop, MD, PhD
  • CME / ABIM MOC / CE Released: 12/1/2022
  • Valid for credit through: 12/1/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.50 ABIM MOC points

    Nurses - 1.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    Pharmacists - 1.50 Knowledge-based ACPE (0.150 CEUs)

    IPCE: 1.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, pathologists, surgeons, nurse practitioners (NPs), physician assistants (PAs), pharmacists, and nurses.

The goal of this activity is for the learners to be better able to understand the spectrum of breast cancer treatment and provide strategies that can help translate data updates to improvements in patient care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Interpretation of testing results to determine therapeutic approaches for patients
    • Emerging therapies targeting HER2-low patients with breast cancer
  • Have greater competence related to
    • Utilizing the overall prognosis of a patient with HER2-positive brain metastases to develop a treatment plan
  • Demonstrate greater confidence in their ability to
    • Incorporate interprofessional strategies into breast cancer care


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Reshma L. Mahtani, DO

    Chief of Breast Medical Oncology
    Miami Cancer Institute
    Baptist Health South Florida
    Plantation, Florida 

    Disclosures

    Reshma L. Mahtani, DO, has the following relevant financial relationships:
    Consultant or advisor for: Agendia; Amgen; AstraZeneca; Biotheranostics; Daiichi Sankyo; Eisai; Genentech; Gilead; Lilly; Merck; Novartis; Pfizer; PUMA; Sanofi; Seagen, Inc.
    Research funding from: Agendia; AstraZeneca; Genentech; Veru

  • Alexandra Zimmer, MD

    Associate Professor of Medicine
    NCI, NIH
    Oregon Health and Science University
    Portland, Oregon 

    Disclosures

    Alexandra Zimmer, MD, has no relevant financial relationships.

  • Michael F. Press, MD, PhD

    Chair in Cancer Research
    Professor of Pathology
    University of Southern California
    Los Angeles, California

    Disclosures

    Michael F. Press, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Biocartis; Cepheid; Lilly USA LLC; Merck; Novartis Pharmaceuticals Corporation; Puma Biotechnology; Zymeworks
    Stock options from: Torl Biotherapeutics

  • Chau T. Dang, MD

    Professor of Medicine
    Weill Cornell Medical College
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Chau T. Dang, MD, has the following relevant financial relationships:
    Consultant or advisor for: Daiichi Sankyo; Evicore; Genentech; Novartis; Pfizer; PUMA; Roche; Seagen, Inc.
    Research funding from: Daiichi Sankyo; Genentech; PUMA; Roche
    Contracted researcher for: Daiichi Sankyo; Genentech; PUMA; Roche

  • Ian Krop, MD, PhD

    Associate Cancer Center Director
    Clinical Research Director
    Clinical Trials Office
    Chief Clinical Research Officer
    Yale Cancer Center
    New Haven, Connecticut

    Disclosures

    Ian Krop, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Macrogenics; Roche; Seagen, Inc.; Taiho Oncology
    Research funding from: Genentech; Macrogenics; Pfizer

Editor

  • Davecia Ragoonath-Cameron, MS

    Medical Education Director, Medscape, LLC

    Disclosures

    Davecia Ragoonath-Cameron, MS, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • • Medscape designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-22-311-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Special Topics in HER2-Positive Breast Cancer

Authors: Reshma L. Mahtani, DO; Alexandra Zimmer, MD; Michael F. Press, MD, PhD; Chau T. Dang, MD; Ian Krop, MD, PhDFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/1/2022

Valid for credit through: 12/1/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

How We Treat Brain Metastases in HER2-Positive ​Breast Cancer​

Dr Alexandra Zimmer delves into the management of brain metastases in HER2-positive breast cancer.
Alexandra Zimmer, MD

HER2 Status: Testing Today

Dr Michael Press covers the latest in HER2 testing.
Michael F. Press, MD, PhD

HER2 Low: Where Are We?

What is the current management of HER2 low breast cancer? Drs Krop and Dang discuss.
Chau T. Dang, MD; Ian Krop, MD, PhD
 

Educational Impact Challenge

The goal of this activity is for the learners to be better able to understand the spectrum of breast cancer treatment and provide strategies that can help translate data updates to improvements in patient care.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print